Citi Downgrades Hospira (HSP) to Sell, Lifts Price Target to $33
Tweet
Share
E-mailGet Alerts HSP Hot Sheet
Price: $89.95 --0%
Rating Summary:
3 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Citi downgraded shares of Hospira (NYSE: HSP) from its previous rating of Neutral to Sell, while raising its price target from $30 to $33.00.
For an analyst ratings summary and ratings history on Hospira click here. For more ratings news on Hospira click here.
Shares of Hospira closed at $37.92 yesterday.
For an analyst ratings summary and ratings history on Hospira click here. For more ratings news on Hospira click here.
Shares of Hospira closed at $37.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
- Goldman Sachs Downgrades Hysan Development Company Limited (14:HK) (HYSNY) to Sell
- UBS Downgrades Vicinity Centers (VCX:AU) (CNRAF) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
